1401
|
Inflow and outflow occlusion technique of the pulmonary artery and veins for the technically difficult left upper lobectomy. Eur J Cardiothorac Surg 2011; 41:353-6. [PMID: 21703861 DOI: 10.1016/j.ejcts.2011.05.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE Our objective is to assess the safety of a surgical technique applied to the difficult left upper lobectomy. The inflow-outflow occlusion technique features: dividing the superior pulmonary vein first, then proximal control by clamping the main pulmonary artery (PA), and then distal control by clamping the inferior pulmonary vein. METHODS A retrospective cohort study of a prospective database was carried out. Patients who underwent left upper lobectomy and required clamping of the vessels were compared to those that did not. RESULTS Between January 1999 and March 2010,1796 lobectomies were performed and 360 (23%) of these were left upper lobectomies. Of these, 84 (23%) required the inflow-outflow occlusion technique. There were 70 (83%) men (median age 65 years). Fifty-one patients (61%) required resection of the PA and 33 did not. Heparin was not used in the last 17 patients. These 84 patients were compared to the remaining 276 patients who underwent standard left upper lobectomy. Although the median operative time was longer (150 vs 105 min, p < 0.001) and the median blood loss was greater (120 vs 87 ml, p = 0.03) for the inflow-outflow technique, there were no significant differences in hospital length of stay, morbidity, or mortality between the two groups. CONCLUSION In our experience, clamping of the inferior pulmonary vein instead of the distal PA achieves safe distal vascular control. It affords greater PA mobility and assessment of the tumor and easier PA repair. This technique can be used even when PA resection is not required.
Collapse
|
1402
|
Lehto RH. Identifying Primary Concerns in Patients Newly Diagnosed With Lung Cancer. Oncol Nurs Forum 2011; 38:440-7. [DOI: 10.1188/11.onf.440-447] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
1403
|
Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer 2011; 117:5538-47. [PMID: 21692074 DOI: 10.1002/cncr.26257] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2011] [Revised: 04/12/2011] [Accepted: 04/12/2011] [Indexed: 01/02/2023]
Abstract
BACKGROUND Lung cancer accounts for the largest absolute risk of second malignancies among Hodgkin lymphoma (HL) survivors. However, no population-based studies have compared overall survival (OS) between HL survivors who developed nonsmall cell lung cancer (HL-NSCLC) versus patients with first primary NSCLC (NSCLC-1). METHODS The authors compared the OS of 178,431 patients who had NSCLC-1 and 187 patients who had HL-NSCLC (among 22,648 HL survivors), accounting for sex, race, sociodemographic status, calendar year, and age at NSCLC diagnosis, and NSCLC histology and stage. All patients were reported to the population-based Surveillance, Epidemiology, and End Results Program. Hazard ratios (HRs) were derived from a Cox proportional hazards model. RESULTS Although the NSCLC stage distribution was similar in both groups (20% localized, 30% regional, and 50% distant), HL survivors experienced significantly inferior stage-specific OS. For patients with localized, regional, and distant stage NSCLC, the HRs (95% confidence interval [CI]) for death among HL survivors were 1.60 (95% CI, 1.08-2.37; P < .0001), 1.67 (95% CI, 1.26-2.22; P = .0004), and 1.31 (95% CI, 1.06-1.61; P = .013), respectively. Among HL-NSCLC patients, significant associations were observed between more advanced NSCLC stage and the following variables: younger age at HL diagnosis (P = .003), younger age at NSCLC diagnosis (P = .048), and longer latency between HL and NSCLC diagnoses (P = .015). CONCLUSIONS Compared with patients who had de novo NSCLC, HL survivors experienced a significant 30% to 60% decrease in OS after an NSCLC diagnosis. Further research is needed to not only elucidate the clinical-biologic underpinnings of NSCLC after HL, including the influence of previous HL treatment, but also to define the role of lung cancer screening in selected patients.
Collapse
Affiliation(s)
- Michael T Milano
- Department of Radiation Oncology and Rubin Center for Cancer Survivorship, University of Rochester School of Medicine, Rochester, New York 14642, USA.
| | | | | | | |
Collapse
|
1404
|
Perroud MW, Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vassallo J, Saad ST, Zambon L. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2011; 30:65. [PMID: 21682877 PMCID: PMC3135553 DOI: 10.1186/1756-9966-30-65] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Accepted: 06/17/2011] [Indexed: 12/31/2022]
Abstract
Background Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC) are poor. The dendritic cell (DC) immunotherapy has been developed as a new strategy for the treatment of lung cancer. The purpose of this study was to evaluate the feasibility, safety and immunologic responses in use in mature, antigen-pulsed autologous DC vaccine in NSCLC patients. Methods Five HLA-A2 patients with inoperable stage III or IV NSCLC were selected to receive two doses of 5 × 107 DC cells administered subcutaneous and intravenously two times at two week intervals. The immunologic response, safety and tolerability to the vaccine were evaluated by the lymphoproliferation assay and clinical and laboratorial evolution, respectively. Results The dose of the vaccine has shown to be safe and well tolerated. The lymphoproliferation assay showed an improvement in the specific immune response after the immunization, with a significant response after the second dose (p = 0.005). This response was not long lasting and a tendency to reduction two weeks after the second dose of the vaccine was observed. Two patients had a survival almost twice greater than the expected average and were the only ones that expressed HER-2 and CEA together. Conclusion Despite the small sample size, the results on the immune response, safety and tolerability, combined with the results of other studies, are encouraging to the conduction of a large clinical trial with multiples doses in patients with early lung cancer who underwent surgical treatment. Trial Registration Current Controlled Trials: ISRCTN45563569
Collapse
Affiliation(s)
- Maurício W Perroud
- Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
1405
|
Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 2011; 74:1-6. [PMID: 21658788 DOI: 10.1016/j.lungcan.2011.05.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2010] [Revised: 04/26/2011] [Accepted: 05/01/2011] [Indexed: 01/13/2023]
Abstract
Lung cancer continues to present an enormous global burden of morbidity and mortality, despite an increasing therapeutic armamentarium of chemotherapy and targeted agents. Recent research efforts have been directed towards identifying predictors of response to treatment, in order to facilitate the selection of patients likely to obtain the greatest benefit from specific therapeutic interventions, with the ultimate goal of providing customized therapy. A strong scientific basis exists for the use of markers to identify patients who are most likely to respond to biological and targeted therapies, based on characteristics such as tumour genotype and histology. Biomarkers have the potential to aid in patient stratification (risk assessment), treatment-response identification (surrogate markers), or differential diagnosis (identifying individuals who are likely to respond well to specific therapies). Numerous trials have demonstrated correlations between molecular biomarkers and the outcome of treatment with targeted therapies such as epidermal growth factor inhibitor tyrosine-kinase inhibitors in patients with non-small-cell lung cancer (NSCLC). The recently completed MarkER Identification Trial (MERIT) found some evidence of a link between the molecular profile of a tumour and the clinical response to erlotinib in patients with relapsed NSCLC. However, MERIT also highlighted the difficulties in obtaining adequate samples for the various procedures involved in genetic analyses in clinical trials. Routine clinical practice brings its own challenges relating to biopsy techniques and tissue availability and this has implications for the application of molecular analyses in treatment decision-making. Applying the lessons learned from tissue sampling and molecular testing in MERIT and other major NSCLC trials will be essential in paving the way for the routine use of biomarker analyses in clinical practice.
Collapse
|
1406
|
Zou JH, An L, Chen S, Ren LQ. XPA A23G polymorphism and lung cancer risk: a meta-analysis. Mol Biol Rep 2011; 39:1435-40. [PMID: 21611749 DOI: 10.1007/s11033-011-0878-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2010] [Accepted: 05/14/2011] [Indexed: 11/28/2022]
Abstract
Case-control studies on the association between XPA A23G and lung cancer have provided either controversial or inconclusive results. To clarify the effect of XPA A23G on the risk of lung cancer, a meta-analysis of all case-control observational studies was performed. Pooled odds ratios (ORs) for various polymorphisms were estimated using random and fixed effects models. The Q-statistic was used to evaluate the homogeneity, and Egger and Begg tests were used to assess publication bias. For the homozygote GG and G allele carriers (GA + GG), the pooled ORs were 1.24 (95% CI 1.05-1.46; P = 0.27 for heterogeneity) and 1.30 (95% CI 1.13-1.51; P = 0.45 for heterogeneity) compared to the homozygous genotype (AA). In the stratified analysis by ethnicity, the ORs of the G allele carriers and the homozygote GG were 1.28 (95% CI 1.10-1.49; P = 0.07 for heterogeneity) and 1.42 (95% CI 1.04-1.93; P = 0.39 for heterogeneity) among non-Caucasians. No significant associations were found in the Caucasian population in any of the genetic models. When studies that were not in Hardy-Weinberg equilibrium (HWE) were corrected, the pattern of the results remained the same. Our results indicated a significantly decreased risk of lung cancer in non-Caucasians with the G allele.
Collapse
Affiliation(s)
- Ji-Hong Zou
- Department of Gerontology, The Affiliated Zhong Da Hospital of Southeast University, 87 Dingjiaqiao, Nanjing 210009, People's Republic of China
| | | | | | | |
Collapse
|
1407
|
Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29:2312-8. [PMID: 21555682 DOI: 10.1200/jco.2010.31.7875] [Citation(s) in RCA: 123] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE Non-small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models, it demonstrates radiosensitization properties. We report a phase II trial testing the combination of cetuximab with chemoradiotherapy (CRT) in unresectable stage III NSCLC. PATIENTS AND METHODS Eligibility criteria included unresectable stage III NSCLC, Zubrod performance status ≤ 1, weight loss ≤ 5%, forced expiratory volume in 1 second ≥ 1.2 L, and adequate organ function. Patients received an initial dose of cetuximab (400 mg/m(2)) on day 1 of week 1 and then weekly doses of cetuximab (250 mg/m(2)) until completion of therapy (weeks 2 through 17). During week 2, patients started CRT (63 Gy in 35 fractions) with weekly carboplatin at area under the [concentration-time] curve (AUC) 2 and six doses of paclitaxel at 45 mg/m(2) followed by carboplatin (AUC 6) and two cycles of paclitaxel (200 mg/m(2)) during weeks 12 through 17. Primary end points included safety and compliance of concurrent cetuximab and CRT. RESULTS In all, 93 patients were enrolled and 87 were evaluable. Median follow-up was 21.6 months. Response rate was 62% (n = 54), median survival was 22.7 months, and 24-month overall survival was 49.3%. Adverse events related to treatment included 20% grade 4 hematologic toxicities, 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis. There were five grade 5 events. CONCLUSION The combination of cetuximab with CRT is feasible and shows promising activity. The median and overall survival achieved with this regimen were longer than any previously reported by the Radiation Therapy Oncology Group.
Collapse
Affiliation(s)
- George R Blumenschein
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
1408
|
Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol 2011; 11:61. [PMID: 21548941 PMCID: PMC3112194 DOI: 10.1186/1471-2288-11-61] [Citation(s) in RCA: 102] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2010] [Accepted: 05/06/2011] [Indexed: 11/17/2022] Open
Abstract
Background Pairwise meta-analysis, indirect treatment comparisons and network meta-analysis for aggregate level survival data are often based on the reported hazard ratio, which relies on the proportional hazards assumption. This assumption is implausible when hazard functions intersect, and can have a huge impact on decisions based on comparisons of expected survival, such as cost-effectiveness analysis. Methods As an alternative to network meta-analysis of survival data in which the treatment effect is represented by the constant hazard ratio, a multi-dimensional treatment effect approach is presented. With fractional polynomials the hazard functions of interventions compared in a randomized controlled trial are modeled, and the difference between the parameters of these fractional polynomials within a trial are synthesized (and indirectly compared) across studies. Results The proposed models are illustrated with an analysis of survival data in non-small-cell lung cancer. Fixed and random effects first and second order fractional polynomials were evaluated. Conclusion (Network) meta-analysis of survival data with models where the treatment effect is represented with several parameters using fractional polynomials can be more closely fitted to the available data than meta-analysis based on the constant hazard ratio.
Collapse
|
1409
|
Evaluation of the Reliability of Electronic Medical Record Data in Identifying Comorbid Conditions among Patients with Advanced Non-Small Cell Lung Cancer. J Cancer Epidemiol 2011; 2011:983271. [PMID: 21765829 PMCID: PMC3134088 DOI: 10.1155/2011/983271] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 02/10/2011] [Accepted: 02/28/2011] [Indexed: 11/17/2022] Open
Abstract
Background. Traditional methods for identifying comorbidity data in EMRs have relied primarily on costly and time-consuming manual chart review. The purpose of this study was to validate a strategy of electronically searching EMR data to identify comorbidities among cancer patients. Methods. Advanced stage NSCLC patients (N = 2,513) who received chemotherapy from 7/1/2006 to 6/30/2008 were identified using iKnowMed, US Oncology's proprietary oncology-specific EMR system. EMR data were searched for documentation of comorbidities common to advanced stage cancer patients. The search was conducted by a series of programmatic queries on standardized information including concomitant illnesses, patient history, review of systems, and diagnoses other than cancer. The validity of the comorbidity information that we derived from the EMR search was compared to the chart review gold standard in a random sample of 450 patients for whom the EMR search yielded no indication of comorbidities. Negative predictive values were calculated. Results. The overall prevalence of comorbidities of 22%. Overall negative predictive value was 0.92 in the 450 patients randomly sampled patients (36 of 450 were found to have evidence of comorbidities on chart review). Conclusion. Results of this study suggest that efficient queries/text searches of EMR data may provide reliable data on comorbid conditions among cancer patients.
Collapse
|
1410
|
Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011; 11:147. [PMID: 21507233 PMCID: PMC3098185 DOI: 10.1186/1471-2407-11-147] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2010] [Accepted: 04/20/2011] [Indexed: 12/26/2022] Open
Abstract
Background Lung cancer is the leading cause of cancer-related death worldwide. Genetic and epigenetic alterations have been identified frequently in lung cancer, such as promoter methylation, gene mutations and genomic amplification. However, the interaction between genetic and epigenetic events and their significance in lung tumorigenesis remains poorly understood. Methods We determined the promoter methylation of 6 genes and PIK3CA amplification using quantitative methylation-specific PCR (Q-MSP) and real-time quantitative PCR, respectively, and explore the association of promoter methylation with PIK3CA amplification in a large cohort of clinically well-characterized non-small cell lung cancer (NSCLC). Results Highly frequent promoter methylation was observed in NSCLC. With 100% diagnostic specificity, excellent sensitivity, ranging from 45.8 to 84.1%, was found for each of the 6 genes. The promoter methylation was associated with histologic type. Methylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC). Conversely, there was a trend toward a higher frequency of RASSF1A methylation in ADC than SCC. In addition, PIK3CA amplification was frequently found in NSCLC, and was associated with certain clinicopathologic features, such as smoking history, histologic type and pleural indentation. Importantly, aberrant promoter methylation of certain genes was significantly associated with PIK3CA amplification. Conclusions Our data showed highly frequent promoter methylation and PIK3CA amplification in Chinese NSCLC population, and first demonstrated the associations of gene methylation with PIK3CA amplification, suggesting that these epigenetic events may be a consequence of overactivation of PI3K/Akt pathway.
Collapse
Affiliation(s)
- Meiju Ji
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an 710061, the People's Republic of China
| | | | | | | | | |
Collapse
|
1411
|
Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 2011; 30:3802-12. [PMID: 21478903 PMCID: PMC3220271 DOI: 10.1038/onc.2011.94] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Cancer progression involves multiple complex and interdependent steps, including progressive proliferation, angiogenesis and metastases. The complexity of these processes requires a comprehensive elucidation of the integrated signaling networks for better understanding. EAPII interacts with multiple cancer-related proteins, but its biological significance in cancer development remains unknown. In this report we identified the elevated level of EAPII protein in non-small-cell lung carcinoma (NSCLC) patients and NSCLC cell lines in culture. The oncogenic role of EAPII in lung cancer development was demonstrated using NSCLC cells with genetic manipulations that influence EAPII expression: EAPII overexpression increases proliferation of NSCLC cells with an accelerated transition of cell cycle and facilitates xenograft tumor growth in vivo; EAPII knockdown results in apoptosis of NSCLC cells and reduces xenograft tumor formation. To further explore the mechanism of EAPII's oncogenic role in lung cancer development and to elucidate the potential signaling pathway(s) that EAPII may impact, we employed antibody array to investigate the alternation of the major signaling pathways in NSCLC cells with altered EAPII level. We found that EAPII overexpression significantly activated Raf1 and ERK1/2, but not c-Jun N-terminal kinase and p38 pathways. Consistently, the protein and mRNA levels of MYC and cyclin D1, which are targets of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK–ERK) pathway, are significantly increased by EAPII overexpression. Taken together, we demonstrated that EAPII is an oncogenic factor and the activation of MAPK–ERK signaling pathway by EAPII may contribute to lung cancer development.
Collapse
|
1412
|
Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. ACTA ACUST UNITED AC 2011; 81:265-84. [PMID: 21430413 DOI: 10.1159/000324601] [Citation(s) in RCA: 167] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Both chronic obstructive pulmonary disease (COPD) and lung cancer are major causes of death worldwide. In most cases this reflects cigarette smoke exposure which is able to induce an inflammatory response in the airways of smokers. Indeed, COPD is characterized by lower airway inflammation, and importantly, the presence of COPD is by far the greatest risk factor for lung cancer amongst smokers. Cigarette smoke induces the release of many inflammatory mediators and growth factors including TGF-β, EGFR, IL-1, IL-8 and G-CSF through oxidative stress pathways and this inflammation may persist for decades after smoking cessation. Mucus production is also increased by these inflammatory mediators, further linking airway inflammation to an important mechanism of lung cancer. A greater understanding of the molecular and cellular pathobiology that distinguishes smokers with lung cancer from smokers with and without COPD is needed to unravel the complex molecular interactions between COPD and lung cancer. By understanding the common signalling pathways involved in COPD and lung cancer the hope is that treatments will be developed that not only treat the underlying disease process in COPD, but also reduce the currently high risk of developing lung cancer in these patients.
Collapse
Affiliation(s)
- Ian M Adcock
- Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.
| | | | | |
Collapse
|
1413
|
Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2011; 30:30. [PMID: 21414214 PMCID: PMC3069944 DOI: 10.1186/1756-9966-30-30] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Accepted: 03/17/2011] [Indexed: 12/18/2022]
Abstract
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have been widely used for the treatment of non-small cell lung cancer (NSCLC). KRAS and EGFR somatic mutations in NSCLC may predict resistance and responsiveness to TKI, respectively. Nevertheless, most research to date has been conducted on samples from primary tumors. For many patients with advanced disease, their samples can only be obtained from metastases for test. The molecular characteristics of metastasized tumors may be different from those of primary tumors. Materials and methods Mutation status of KRAS and EGFR between primary tumors and local lymph node metastases of 80 Chinese patients with NSCLC were analyzed by direct sequencing. Five of them were given gefitinib as neoadjunvant treatment after the EGFR-TKI sensitive mutations were detected in their biopsies of mediastinal lymph nodes metastases. McNemar's test was used to compare the EGFR and KRAS mutation status between primary tumors and corresponding local lymph node metastases. Data evaluation was carried out with SPSS_13.0 statistical software. Results Among the 160 samples, one primary tumor and seven metastases were identified with KRAS mutations and 21 primary tumors and 26 metastases were found to have EGFR mutations. KRAS and EGFR mutation status was different between primary tumors and corresponding metastases in 6 (7.5%) and 7 (8.75%) patients, respectively. One patient with no TKI sensitive mutations detected in the primary tumor showed disease progression. Conclusion Our results suggest that a considerable proportion of NSCLC in Chinese population showed discrepancy in KRAS and EGFR mutation status between primary tumors and corresponding metastases. This observation may have important implication for the use of targeted TKI therapy in the treatment of NSCLC patients.
Collapse
Affiliation(s)
- Leina Sun
- Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, China
| | | | | | | | | | | |
Collapse
|
1414
|
赵 肖, 王 孟. [Clinical utility of serum tumor markers in lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2011; 14:286-91. [PMID: 21426676 PMCID: PMC5999651 DOI: 10.3779/j.issn.1009-3419.2011.03.16] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/16/2010] [Revised: 01/14/2011] [Indexed: 12/23/2022]
Abstract
Lung cancer shows a tendency of higher incidence and higher mortality in recent years, but the overall 5-year survival rate is less than 15%. Serum tumor markers of lung cancer play an important role in early diagnosis, determining of pathology types, staging, evaluation of response, and prognosis of lung cancer. In this review, 6 most important markers were reviewed, including neuron-specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP), cytokeratin 19 fragments (Cyfra 21-1), tissue polypeptide antigen (TPA), squamous cell carcinoma associated antigen (SCC-Ag), carcinoembryonic antigen (CEA).
Collapse
Affiliation(s)
- 肖 赵
- />100730 北京,中国医学科学院,中国协和医科大学,北京协和医院呼吸内科Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| | - 孟昭 王
- />100730 北京,中国医学科学院,中国协和医科大学,北京协和医院呼吸内科Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
| |
Collapse
|
1415
|
Moreland SS. Nutrition screening and counseling in adults with lung cancer: a systematic review of the evidence. Clin J Oncol Nurs 2011; 14:609-14. [PMID: 20880818 DOI: 10.1188/10.cjon.609-614] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Maintenance of adequate nutrition is an integral component of the cancer treatment process. Numerous factors should be considered when evaluating the nutritional status of patients with cancer. A systematic review of the literature revealed the importance of nutrition interventions in patients with cancer who were undergoing chemotherapy. Counseling in nutrition has been shown to improve quality of life, strengthen response to therapy, and increase survival. Lung cancer presents a significant risk as the leading cause of cancer morbidity and mortality in the United States. In addition, nutritional deficiencies are experienced by most adults with lung cancer during the course of their disease and treatment. The deficiencies compound the cost of treatment and also increase morbidity and mortality in this patient population. Further study of nutritional interventions is needed to promote better outcomes and quality of life in patients with lung cancer.
Collapse
Affiliation(s)
- Susan S Moreland
- School of Nursing, Catholic University of America, Washington, DC, USA.
| |
Collapse
|
1416
|
Hung R, Krebs P, Coups EJ, Feinstein MB, Park BJ, Burkhalter J, Ostroff JS. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manage 2011; 41:426-35. [PMID: 21216563 PMCID: PMC3063865 DOI: 10.1016/j.jpainsymman.2010.05.017] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2009] [Revised: 05/05/2010] [Accepted: 05/06/2010] [Indexed: 12/22/2022]
Abstract
CONTEXT Fatigue is the most common sequela among non-small cell lung cancer (NSCLC) survivors one to six years post-treatment and is associated with functional limitations. OBJECTIVES This study examined the prevalence, severity, and correlates of fatigue among early stage NSCLC survivors. METHODS Three-hundred fifty individuals diagnosed and surgically treated for Stage IA or IB NSCLC completed a survey that included the Brief Fatigue Inventory (BFI) to assess the prevalence and severity of fatigue. The Karnofsky Self-Reported Performance Rating scale (SR-KPS) was used as a measure of functional status and was compared with the severity of fatigue through Chi-squared analyses. Demographic, psychological, and medical correlates of fatigue were examined using logistic regression. RESULTS The prevalence of fatigue was 57%. Forty-one percent (n=142) of participants had mild fatigue and 16.8% (n=59) had moderate or severe fatigue (BFI≥4). Among the individuals reporting moderate or severe fatigue, 23.7% (n=14) had significant functional impairment (SR-KPS≤70%) compared with 2.8% (n=8) with mild or no fatigue (χ(2)=58.1, P<0.001). In the multivariate analysis, NSCLC survivors with pulmonary disease (odds ratio [OR]=2.28), depressive symptoms (OR=6.99), and anxiety symptoms (OR=2.31) were more likely to report experiencing clinically significant fatigue, whereas those who met physical activity guidelines (OR=0.29) reported less fatigue. CONCLUSION Fatigue is highly prevalent among NSCLC survivors and associated with more functional impairment. A comprehensive approach to the treatment of fatigue includes the screening and management of anxious and depressive symptoms, and pulmonary disorders such as chronic obstructive pulmonary disease.
Collapse
Affiliation(s)
- Robert Hung
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
| | | | | | | | | | | | | |
Collapse
|
1417
|
McMillen E, Ye F, Li G, Wu Y, Yin G, Liu W. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res 2011; 36:531-7. [PMID: 20939760 DOI: 10.3109/01902148.2010.482176] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Lung cancer, specifically non-small cell lung cancer (NSCLC), is a leading cause of mortality worldwide. In China, a dramatic increase in the incidence of NSCLC is expected in the next 20 years (Molina et al. Mayo Clin Proc. 2008;83:584–594). Mutated epidermal growth factor receptor (EGFR) status is a known predictor of response to tyrosine kinase inhibitors (TKIs), and immunohistochemistry may be a less costly way of predicting presence of mutation. In this study, mutation analysis of EGFR in 218 cases of NSCLC was performed. One hundred thirty tissue samples were examined via immunohistochemistry of p-EGFR (Y1045 and Y1068) and correlated with mutation status. Mutations were seen in 29% of patients, and were correlated with female sex, nonsmoking history, and adenocarcinoma histology. Phosphorylation at Y1045 was noted in 52% of cases, but in 71% of cases with EGFR mutation (P = .003). Phosphorylation of Y1068 was seen in 55% of cases but in 73% of cases with EGFR mutation (P = .006). This study correlating EGFR mutation with p-EGFR expression in resected NSCLC is one of the largest to date, although TKI response could not be assessed. The data show that, among Chinese patients, detection of p-1045 and p-1068 expression with immunohistochemistry predicts EGFR mutations. Immunohistochemical analysis of p-EGFR may be useful to predict responses to TKI therapy, although future studies are necessary.
Collapse
Affiliation(s)
- Elizabeth McMillen
- Department of Pathology, Mount Sinai School of Medicine, New York, New York, USA
| | | | | | | | | | | |
Collapse
|
1418
|
|
1419
|
Crapanzano JP, Loukeris K, Borczuk AC, Saqi A. Cytological, histological, and immunohistochemical findings of pulmonary carcinomas with basaloid features. Diagn Cytopathol 2011; 39:92-100. [DOI: 10.1002/dc.21335] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
1420
|
Navalkissoor S, Szyszko T, Rankin S, Gnanasegaran G. Differential uptake of 18F-FDG in patients with synchronous lung cancers. Ann Nucl Med 2011; 25:299-302. [PMID: 21234727 DOI: 10.1007/s12149-010-0457-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2010] [Accepted: 11/21/2010] [Indexed: 10/18/2022]
Abstract
(18)F-fluoro-2-deoxy-D: -glucose positron emission tomography ((18)F-FDG PET/CT) has developed into the standard of care for investigating patients with non-small cell lung cancer (NSCLC) to determine the optimal treatment. However, although the majority of patients with NSCLC do have intense uptake of tracer, false negatives do occur and should be considered. We report cases of patients that have synchronous NSCLCs. In both cases, there was intense uptake of FDG in one tumour type, with very low grade uptake in the separate tumour. Histology confirmed separate lung malignancies, demonstrating that differential FDG uptake may not always be inflammatory and should be considered to have a separate malignant aetiology.
Collapse
|
1421
|
EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 2011; 67:235-43. [DOI: 10.1007/s00228-010-0965-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2010] [Accepted: 11/25/2010] [Indexed: 11/25/2022]
|
1422
|
Andjelkovic T, Bankovic J, Stojsic J, Milinkovic V, Podolski-Renic A, Ruzdijic S, Tanic N. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 2011; 157:19-28. [PMID: 21146147 DOI: 10.1016/j.trsl.2010.09.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2010] [Revised: 09/07/2010] [Accepted: 09/21/2010] [Indexed: 12/14/2022]
Abstract
The inactivation of p53 and PTEN tumor suppressor genes is a common genetic event in lung cancer. However, data on the effect of the joint inactivation of tumor-suppressor genes in non-small cell lung carcinoma (NSCLC) are lacking. The purpose of this study was to investigate the alterations in PTEN and p53 genes, as well as to evaluate their mutual role in NSCLC pathogenesis and their impact on survival rate. To that end, polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP), sequencing, methylation-specific PCR, and fragment analysis were used. The results obtained were correlated with clinicopathologic parameters, the level of genomic instability, and patient survival. Overall, 13% of specimens had aberrant p53 only, 13% had inactive PTEN only, and 50% of samples had both genes altered. Correlation analyses showed that the mutual inactivation of p53 and PTEN was a frequent event that was associated significantly with the increased level of genomic instability and lymph node invasion implying their synergistic effect in promoting metastatic phenotype of this kind of cancer. In addition, our results revealed a significant association of joint alterations of these genes with dramatically shortened survival indicating that aberrant p53 and PTEN could be used as an adverse prognostic factor for NSCLC patients' outcome. Our findings established the relevance of the combinatorial inactivation of p53 and PTEN in NSCLC progression and identified a subgroup of patients with a particularly aggressive disease.
Collapse
Affiliation(s)
- Tijana Andjelkovic
- Department of Neurobiology University of Belgrade, Institute for Biological Research, Republic of Serbia
| | | | | | | | | | | | | |
Collapse
|
1423
|
Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol 2011; 123:30-6. [PMID: 20955794 PMCID: PMC3010457 DOI: 10.1016/j.jsbmb.2010.10.002] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2010] [Revised: 10/08/2010] [Accepted: 10/11/2010] [Indexed: 12/12/2022]
Abstract
Vitamin D has been shown to have anti-proliferative effects in a wide variety of cancers including lung cancer. The anticancer effects of vitamin D are mediated primarily by its active metabolite, 1,25-dihydroxyvitamin D (calcitriol), through vitamin D receptor (VDR) signaling. However, thus far there have been no studies evaluating the association between VDR expression and survival outcome in lung cancer. Using immunohistochemical analysis, we evaluated VDR expression, separately in the nucleus and cytoplasm, in lung cancer samples from 73 non-small cell lung carcinoma (NSCLC) patients with no prior therapy, and investigated the association between VDR expression and overall survival (OS). Cox proportional hazard models were used for our primary analyses. There were 44 deaths during a median follow-up of 51 months (range 13-93 months). High nuclear VDR expression was associated with improved OS after adjusting for age, gender, stage, smoking status, and histology (adjusted hazard ratio, 0.36; 95% confidence interval, 0.17-0.79). There was no association between cytoplasmic VDR expression and OS. Our results suggest that nuclear VDR status may be a prognostic marker in NSCLC. Future large studies to replicate our findings and to assess the impact of VDR gene polymorphisms on VDR expression are required as therapies targeting the vitamin D signaling pathway may be influenced by VDR status in the target lung cancer tissue.
Collapse
Affiliation(s)
- Malini Srinivasan
- Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA.
| | | | | | | | | |
Collapse
|
1424
|
Zhan X, Dong H, Sun C, Liu L, Wang D, Wei Z. [Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:877-81. [PMID: 20840817 PMCID: PMC6000342 DOI: 10.3779/j.issn.1009-3419.2010.09.08] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
背景与目的 蛋白质的磷酸化和去磷酸化是肺癌发生的重要机制,而吸烟是导致肺癌发生发展的重要危险因素,本研究旨在探讨蛋白酪氨酸磷酸酶SHP2在非小细胞肺癌(non-small cell lung cancer, NSCLC)和小细胞肺癌(small cell lung cancer, SCLC)肿瘤组织中的表达及其临床意义,并初步探讨不同的吸烟指数与SHP2表达水平的关系及可能机制。 方法 采用免疫组织化学技术(Invision法)和荧光原位杂交技术(FISH法)检测53例肺癌组织中SHP2的表达和SHP2 mRNA的扩增情况。 结果 SHP2在15例正常支气管上皮内弱阳性率为80%(亦为总阳性率);在48例NSCLC中弱阳性率为35.4%,中度阳性率为43.8%,强阳性率为6.2%(总阳性率为85.4%);在5例SCLC中弱阳性率为0%,中度阳性率为80%,强阳性率为20%(总阳性率为100%)。SHP2在27例非吸烟NSCLC患者肿瘤组织中的弱阳性率为40.7%,中度阳性率为37.4%,强阳性率为3.7%(总阳性率为81.5%);SHP2在吸烟指数≥400的21例NSCLC患者肿瘤组织中弱阳性率为23.8%,中度阳性率为71.4%,强阳性率为4.7%(总阳性率为100%)。等级计数资料秩和检验结果表明,肺癌组织中SHP2表达的阳性率显著高于正常支气管上皮(P<0.05),SCLC中SHP2的阳性率高于NSCLC(P<0.05),吸烟指数≥400的NSCLC癌组织中SHP2阳性率高于非吸烟患者(P<0.05)。 结论 吸烟NSCLC患者肿瘤组织中SHP2的高表达可能与吸烟相关;SHP2可能在肺癌发生发展中起一定的作用;SHP2可能为肺癌治疗的药物研发提供新思路。
Collapse
Affiliation(s)
- Xuemei Zhan
- Department of Pathology, Linyi People's Hospital of Shandong Province, Linyi 276003, China
| | | | | | | | | | | |
Collapse
|
1425
|
Zhao H, Gu J, Hua F, Xu H, Li L, Yang B, Han Y, Liu S, Hong S. [A meta-analysis of the timing of chest radiotherapy in patients with limited-stage small cell lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:892-7. [PMID: 20840819 PMCID: PMC6000350 DOI: 10.3779/j.issn.1009-3419.2010.09.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
背景与目的 研究结果显示序贯化放疗是小细胞肺癌主要的治疗手段,它可以提高患者的生存率,但是何时开始实施放疗仍然存在争议。本研究旨在探讨放疗实施时间对局限期小细胞肺癌预后的影响。 方法 通过计算机检索Medline、CENTRAL(the Cochrane central register of controlled trials)、中国生物医学文献数据库系统(CBM)、中国期刊全文数据库(CNKI)等收集国内外公开发表的关于早期放疗(化疗开始后30天内开始放疗)对比后期放疗(化疗开始30天以后开始放疗)治疗局限期小细胞肺癌的随机对照研究。应用统计软件Stata 11.0进行数据分析。研究人群为局限期小细胞肺癌;干预措施为胸部放疗+化疗;结局指标为2/3年死亡率和放疗相关副反应。以优势比(odds ratio, OR)及相应的95%置信区间(confidence interval, CI)作为效应指标对结局进行比较。Q统计量的I2检验来检测各研究间的统计学异质性。双侧P<0.05认为各研究间存在明显的异质性。采用Begg法对发表偏倚进行量化检测。 结果 最终纳入分析的文章6篇,共1 189例患者,其中早期放疗组587例,后期放疗组602例。接受早期放疗与接受后期放疗相比,两者2/3年生存优势差别无统计学意义(OR=0.78, 95%CI: 0.55-1.05, P=0.093);单独分析放疗性肺炎(OR=1.93, 95%CI: 0.97-3.86, P=0.797)疗性食管炎(OR=1.43, 95%CI: 0.95-2.13, P=0.572)相关血小板减少(OR=1.23, 95%CI: 0.88-1.77, P=0.746)差别均无统计学意义。 结论 接受早期放疗与接受后期放疗相比,2/3年生存优势、放疗相关副反应无明显区别。
Collapse
Affiliation(s)
- Hui Zhao
- Deapartment of Thoracic Surgery, Tianjin People's Hospital, Tianjin 300121, China
| | | | | | | | | | | | | | | | | |
Collapse
|
1426
|
Ji YN, Zhan P, Wang J, Qiu LX, Yu LK. APE1 Asp148Glu gene polymorphism and lung cancer risk: a meta-analysis. Mol Biol Rep 2010; 38:4537-43. [PMID: 21132382 DOI: 10.1007/s11033-010-0584-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Accepted: 11/20/2010] [Indexed: 02/02/2023]
Abstract
Many studies have examined the association between the APE1 T1349G (Asp148Glu) gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed, Embase, Web of Science, and CNKI database was searched for case-control studies published up to June 2010. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Ultimately, ten studies, comprising 2,696 lung cancer cases and 3,948 controls were included. Overall, for the G allele carriers (TG + GG) versus homozygote TT, the pooled OR was 1.037 (95% CI = 0.928-1.159 P = 0.001 for heterogeneity), for GG versus TT the pooled OR was 0.997 (95% CI = 0.861-1.154 P = 0.005 for heterogeneity). In the stratified analysis by ethnicity, significantly risks were not found among Asians or Caucasians. However, in the subgroup analyses by smoking status, significantly risks were found among smokers not in non-smokers. This meta-analysis suggested that the APE1 T1349G (Asp148Glu) polymorphism was not associated with lung cancer risk among Asians or Caucasians. But, the APE1 G allele was an increased risk factor for developing lung cancer among smokers.
Collapse
Affiliation(s)
- Ya-Nan Ji
- Jiangsu Province Hospital of Traditional Chinese Medicine, 155 Hanzhong Road, 210029 Nanjing, China
| | | | | | | | | |
Collapse
|
1427
|
Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment. Pharm Res 2010; 28:762-75. [PMID: 21116692 DOI: 10.1007/s11095-010-0329-x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2010] [Accepted: 11/12/2010] [Indexed: 01/20/2023]
Abstract
PURPOSE Temozolomide dry powder formulations for inhalation, performed with no excipient or with a lipid or lactose coating, have been evaluated. METHODS The particle size of raw temozolomide in suspension was reduced by a high-pressure homogenizing technique, and the solvent was evaporated by spray-drying to obtain a dry powder. The physicochemical properties of this powder were evaluated and included its crystalline state, thermal properties, morphology, particle size and moisture and drug content, and these properties were determined by X-ray powder diffraction, differential scanning calorimetry, scanning electron microscopy, laser light scattering, thermogravimetric analysis and high-performance liquid chromatography, respectively. The aerodynamic properties and release profiles were also evaluated using a multistage liquid impinger and a modified USP type 2 dissolution apparatus adapted for inhaler products, respectively. RESULTS The dry powder inhalation formulations had a high temozolomide content that ranged from 70% to 100% in the crystalline state and low moisture content. Aerodynamic evaluations showed high fine-particle fractions of up to 51% related to the metered dose. The dissolution profile revealed a similarly fast temozolomide release from the formulations. CONCLUSIONS Dry temozolomide powder formulations, based on the use of acceptable excipients for inhalation and showing good dispersion properties, represent an attractive alternative for use in local lung cancer therapy.
Collapse
|
1428
|
Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, DeCresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer 2010; 129:133-42. [PMID: 20824709 DOI: 10.1002/ijc.25644] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Accepted: 08/06/2010] [Indexed: 11/06/2022]
Abstract
We recently reported the development of a multianalyte serum algorithm to identify nodal status in non-small cell lung cancer (NSCLC) patients facing an anatomic resection with curative intent. This study aims to enhance the overall performance characteristics of this test by adding autoantibody biomarkers identified through immunoproteomic discovery. More specifically, we used sera from 20 NSCLC patients to probe 2-D immunoblots of HCC827 lysates for tumor-associated autoantigens. Relevant differences in immunoreactivity associated with pathological nodal status were then identified via tandem mass spectrometry. Identified autoantigens were then developed into Luminex immunobead assays alongside a series of autoantigen targets relevant to early-disease detection. These assays were then used to measure circulating autoantibody levels in the identical cohort of NSCLC patients used in our original study. This strategy identified 11 autoantigens found primarily in patients with disease progression to the locoregional lymph nodes. Custom Luminex-based "direct-capture" assays (25 total; including autoantibody targets relevant to early-disease detection) were assembled to measure autoantibody levels in sera from 107 NSCLC patients. Multivariate classification algorithms were then used to identify the optimal combination of biomarkers when considered collectively with our original 6-analyte serum panel. The new algorithm resulting from this analysis consists of TNF-α, TNF-RI, MIP-1α and autoantibodies against Ubiquilin-1, hydroxysteroid-(17-β)-dehydrogenase, and triosephosphate isomerase. The inclusion of autoantibody biomarkers provided a dramatic improvement in the overall test performance characteristics, relative to the original test panel, including an 11% improvement in the classification efficiency.
Collapse
Affiliation(s)
- Kalpa Patel
- Department of Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1429
|
Abstract
Current non-small cell lung cancer (NSCLC) chemotherapy and radiotherapy regimens, although showing definite survival benefit, still leave patients with a disappointing 15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research has focused on identifying specific tumorigenic pathways that may serve as therapeutic targets. The most successful strategies to date are those aimed at the epidermal growth factor receptor (EGFR), which is found to be upregulated in 40%-80% of NSCLC. Several tyrosine kinase inhibitors and monoclonal antibodies (mAbs) have been developed that inhibit the EGFR receptor and have demonstrated clinical benefit in trials as single agents and in combination regimens. Here we discuss one such agent, the mAb nimotuzumab, the background of its development, its clinical experience in NSCLC thus far, and the rationale for expanding its use to other NSCLC treatment settings.
Collapse
Affiliation(s)
- William Boland
- Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada
| | | |
Collapse
|
1430
|
Kikawa KD, Herrick JS, Tateo RE, Mouradian M, Tay JS, Pardini RS. Induced Oxidative Stress and Cell Death in the A549 Lung Adenocarcinoma Cell Line by Ionizing Radiation Is Enhanced by Supplementation With Docosahexaenoic Acid. Nutr Cancer 2010; 62:1017-24. [DOI: 10.1080/01635581.2010.492084] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
1431
|
Abstract
Confronting the reality of death is an important challenge for individuals facing life-threatening illness such as lung cancer, the leading cause of cancer death. Few studies, however, document the nature of death-related concerns in individuals newly diagnosed with lung cancer. The aims of this exploratory study were to examine unsolicited death-related concerns among newly diagnosed individuals, and to determine if age, gender, marital status, stage of disease, type of treatment, presence of comorbid conditions, and veteran status were related to extent of death concerns. A mixed-method approach was used to examine death concerns in 73 individuals newly diagnosed with non-small cell lung cancer. Seven categories related to death were identified: psychological preparation, time left, impact, behavioral preparation, acceptance, cancer death experiences, and post-death. Stage of disease and veteran status were factors that were related to increased numbers of death-related content. Findings demonstrate that death concerns are varied, primarily negative, and are relevant to the person facing a new lung cancer diagnosis, thus highlighting the importance for health care providers to assess, discuss, and listen for death concerns in the acute care setting.
Collapse
Affiliation(s)
- Rebecca Lehto
- Michigan State University College of Nursing, East Lansing, Michigan, USA.
| | - Barbara Therrien
- University of Michigan School of Nursing, Ann Arbor, Michigan, USA
| |
Collapse
|
1432
|
Vanags A, Strumfa I, Gardovskis A, Borošenko V, Aboliņš A, Teibe U, Trofimovičs G, Miklaševičs E, Gardovskis J. Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered Cancer Clin Pract 2010; 8:8. [PMID: 21034437 PMCID: PMC2978132 DOI: 10.1186/1897-4287-8-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2010] [Accepted: 10/29/2010] [Indexed: 01/22/2023] Open
Abstract
Background The growing possibilities of cancer prevention and treatment as well as the increasing knowledge about hereditary cancers require proper identification of the persons at risk. The aim of this study was to test the outcome of population screening in the scientific and practical evaluation of hereditary cancer. Methods Population screening for hereditary cancer was carried out retrospectively in a geographic area of Latvia. Family cancer histories were collected from 18642 adults representing 76.6% of the population of this area. Hereditary cancer syndromes were diagnosed clinically. Molecular testing for BRCA1 founder mutations 300 T/G, 4153delA and 5382insC was conducted in 588 persons who reported at least one case of breast or ovary cancer among blood relatives. Results Clinically, 74 (0.40%; 95% confidence interval (CI): 0.32 - 0.50%) high-risk and 548 (2.94%, 95% CI: 2.71 - 3.19) moderate-risk hereditary cancer syndromes were detected covering wide cancer spectrum. All syndromes were characterised by high cancer frequency among blood relatives ranging 8.6 - 46.2% in contrast to spouse correlation of 2.5 - 3.6%. The mean age of cancer onset ranged 38.0 - 72.0 years in different syndromes. The BRCA1 gene mutations were identified in 10 (1.7%; 95% CI: 0.9 - 3.1%) probands. Families with established BRCA1 gene founder mutations were identified with the frequency 1:2663 clinically screened persons. Conclusions Population screening is a useful practical tool for the identification of persons belonging to families with high frequency of malignant tumours. The whole hereditary and familial cancer spectrum along with the age structure was identified adjusting follow-up guidelines. Another benefit of the population screening is the possibility to identify oncologically healthy persons belonging to hereditary and familial cancer families so that appropriate surveillance can be offered. Clinical diagnostics is appropriate for population screening purposes; molecular investigation provides additional information. In collaboration with family doctors, the screening is technically manageable as characterised by high compliance.
Collapse
Affiliation(s)
- Andrejs Vanags
- Hereditary Cancer Institute, Rīga Stradiņš University, Dzirciema Street 16, LV 1007, Riga, Latvia.
| | | | | | | | | | | | | | | | | |
Collapse
|
1433
|
Dong J, Su SY, Wang MY, Zhan Z. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 2010; 29:137. [PMID: 20969765 PMCID: PMC2972256 DOI: 10.1186/1756-9966-29-137] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2010] [Accepted: 10/22/2010] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Platinum-based chemotherapy has been a standard therapy for advanced non-small cell lung cancer (NSCLC), but it has high toxicity. In China, Shenqi Fuzheng, a newly developed injection concocted from Chinese medicinal herbs has been reported that may increase efficacy and reduce toxicity when combined with platinum-based chemotherapy, but little is known about it outside of China. The aim of this study was to systematically review the existing clinical evidence on Shenqi Fuzheng Injection(SFI) combined with platinum-based chemotherapy for advanced NSCLC. METHODS Pubmed, Cochrane Library, EMBASE, CNKI, and CBM search were organized for all documents published, in English and Chinese, until April 2010. The randomized controlled clinical trials were selected based on specific criteria, in which a SFI plus platinum-based chemotherapy treatment group was compared with a platinum-based chemotherapy control group for patients with advanced NSCLC. The quality of studies was assessed by modified Jadad's scale, and Revman 4.2 software was used for data syntheses and analyses. RESULTS Twenty nine studies were included in this review based on our selection criteria. Of them, ten studies were of high quality and the rest were of low quality, according to the modified Jadad scale. The meta-analysis showed there was a statistically significant higher tumor response (RR, 1.19; 95% CI, 1.07 to 1.32; P = 0.001) and performance status ((RR, 1.57; 95% CI, 1.45 to 1.70; P < 0.00001); but lower severe toxicity for WBC (RR, 0.37; 95% CI, 0.29 to 0.47; P < 0.00001), PLT (RR, 0.33; 95% CI, 0.21 to 0.52; P < 0.00001), HB (RR, 0.44; 95% CI, 0.30 to 0.66; P < 0.0001) and nausea and vomiting (RR, 0.32; 95% CI, 0.22 to 0.47; P < 0.00001), when the SFI plus platinum-based chemotherapy treatment group was compared with the platinum-based chemotherapy control group. Sensitivity analysis was restricted to studies with the high quality, and the result was similar when the studies with low quality were excluded. Asymmetry was observed in a funnel plot analysis, and Egger's test also indicated an evidence of publication bias (P = 0.016). CONCLUSIONS SFI intervention appears to be useful to increase efficacy and reduce toxicity when combined with platinum-based chemotherapy for advanced NSCLC, although this result needs to be further verified by more high-quality trials.
Collapse
Affiliation(s)
- Ju Dong
- Institute of Basic Medical Science, Nanjing University of Traditional Chinese Medicine, Nanjing, P.R China
| | - Shi-Yue Su
- Chuzhou City People's Hospital The Second Party, Chuzhou, P.R China
| | - Min-Yan Wang
- Institute of Basic Medical Science, Nanjing University of Traditional Chinese Medicine, Nanjing, P.R China
| | - Zhen Zhan
- Institute of Basic Medical Science, Nanjing University of Traditional Chinese Medicine, Nanjing, P.R China
| |
Collapse
|
1434
|
Jin Y, Xu H, Zhang C, Kong Y, Hou Y, Xu Y, Xue S. Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China. BMC Cancer 2010; 10:422. [PMID: 20704749 PMCID: PMC3087325 DOI: 10.1186/1471-2407-10-422] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2010] [Accepted: 08/12/2010] [Indexed: 12/01/2022] Open
Abstract
Background Cigarette smoking is the most established risk factor, and genetic variants and/or gene promoter methylations are also considered to play an essential role in development of lung cancer, but the pathogenesis of lung cancer is still unclear. Methods We collected the data of 150 cases and 150 age-matched and sex-matched controls on a Hospital-Based Case-Control Study in China. Face to face interviews were conducted using a standardized questionnaire. Gene polymorphism and methylation status were measured by RFLP-PCR and MSP, respectively. Logistic regressive model was used to estimate the odds ratios (OR) for different levels of exposure. Results After adjusted age and other potential confounding factors, smoking was still main risk factor and significantly increased 3.70-fold greater risk of NSCLC as compared with nonsmokers, and the ORs across increasing levels of pack years were 1, 3.54, 3.65 and 7.76, which the general dose-response trend was confirmed. Our striking findings were that the risk increased 5.16, 8.28 and 4.10-fold, respectively, for NSCLC with promoter hypermethylation of the p16, DAPK or RARβ gene in smokers with CYP1A1 variants, and the higher risk significantly increased in smokers with null GSTM1 and the OR was 17.84 for NSCLC with p16 promoter hypermethylation, 17.41 for DAPK, and 8.18 for RARβ in smokers with null GSTM1 compared with controls (all p < 0.01). Conclusion Our study suggests the strong combined effects of cigarette smoke, CYP1A1 and GSTM1 Polymorphisms, hypermethylations of p16, DAPK and RARβ promoters in NSCLC, implying complex pathogenesis of NSCLC should be given top priority in future research.
Collapse
Affiliation(s)
- Yongtang Jin
- Department of Environmental Medicine or Institute of Environmental Medicine, Zhejiang University School of Medicine, Zhejiang University, 310058 Hangzhou, China.
| | | | | | | | | | | | | |
Collapse
|
1435
|
Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010; 78:289-301. [PMID: 20699622 DOI: 10.1159/000319937] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Accepted: 03/21/2010] [Indexed: 11/19/2022]
Abstract
UNLABELLED Lung cancer is the leading cause of cancer death in the US. About 50% of lung cancer patients are current smokers at the time of diagnosis and up to 83% continue to smoke after diagnosis. A recent study suggests that people who continue to smoke after a diagnosis of early-stage lung cancer almost double their risk of dying. Despite a growing body of evidence that continued smoking by patients after a lung cancer diagnosis is linked with less effective treatment and a poorer prognosis, the belief prevails that treating tobacco dependence is useless. With improved cancer treatments and survival rates, smoking cessation among lung cancer patients has become increasingly important. There is a pressing need to clarify the role of smoking cessation in the care of lung cancer patients. OBJECTIVE This paper will report on the benefits of smoking cessation for lung cancer patients and the elements of smoking cessation treatment, with consideration of tailoring to the needs of lung cancer patients. RESULTS Given the significant benefits of smoking cessation and that tobacco dependence remains a challenge for many lung cancer patients, cancer care providers need to offer full support and intensive treatment with a smoking cessation program that is tailored to lung cancer patients' specific needs. CONCLUSION A tobacco dependence treatment plan for lung cancer patients is provided.
Collapse
Affiliation(s)
- Janine K Cataldo
- Department of Physiological Nursing - Gerontology, University of California San Francisco, San Francisco, CA 94143-0610, USA.
| | | | | |
Collapse
|
1436
|
Hu Z, Shen-Tu Y, Ding Z, Tan Q, Zhou Y. [Study on the prognosis of the T1a non-small cell lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:206-10. [PMID: 20673517 PMCID: PMC6000531 DOI: 10.3779/j.issn.1009-3419.2010.03.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2009] [Revised: 01/06/2010] [Indexed: 11/24/2022]
Abstract
背景与目的 新的第7版非小细胞肺癌(non-small cell Lung cancer, NSCLC)分期已经提出肿瘤直径对NSCLC预后的重要性,但是对癌灶直径≤2 cm预后研究尚少。本研究旨在探讨影响癌灶≤2 cm(T1a)的Ⅰ期NSCLC病人的临床预后因素,为临床预后治疗提供依据。 方法 回顾性分析本院既往手术后病理诊断为癌灶≤2 cm(T1a)的Ⅰ期的73例NSCLC病人,运用统计学软件SPSS 17.0分析影响长期生存的临床因素。 结果 该类患者5年以上总体生存率达到80.8%。性别(P=0.175)、年龄(P=0.241)、病理类型(P=0.265)、是否行系统纵隔淋巴结清扫手术(P=0.918)、是否术后辅助化疗(P=0.616)、是否侵犯胸膜(P=0.827)和该类患者的长期生存无明显相关性。影响预后的主要因素是癌灶的分化程度,即在中度分化程度以下长期生存较差(P=0.01)。 结论 在癌症直径≤2 cm的Ⅰ期肺癌中,侵犯胸膜对生存无影响,而分化程度是一个重要的独立预后因素。
Collapse
Affiliation(s)
- Zhongwu Hu
- Shanghai Jiao Tong University Medical College, Shanghai Chest Hospital, Shanghai Lung Tumor Clinical Medical Center, Shanghai 200030, China
| | | | | | | | | |
Collapse
|
1437
|
Yi D, Wiedmann TS. Inhalation Adjuvant Therapy for Lung Cancer. J Aerosol Med Pulm Drug Deliv 2010; 23:181-7. [DOI: 10.1089/jamp.2009.0787] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Dandan Yi
- University of Minnesota, Department of Pharmaceutics, Minneapolis, Minnesota
| | - Timothy Scott Wiedmann
- University of Minnesota, Department of Pharmaceutics, Minneapolis, Minnesota
- MedDiscerna, New Brighton, Minnesota
| |
Collapse
|
1438
|
Mathieu A, Weynand B, Verbeken E, Da Silva S, Decaestecker C, Salmon I, Demetter P. Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 2010; 69:46-50. [DOI: 10.1016/j.lungcan.2009.09.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Revised: 08/17/2009] [Accepted: 09/03/2009] [Indexed: 10/20/2022]
|
1439
|
Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 2010; 28:661-9. [PMID: 20394501 DOI: 10.3109/07357901003735634] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
To evaluate the prognostic value of matrix metalloproteinase2 (MMP-2) expression in patients with non-small cell lung cancer (NSCLC), the electronic database PubMed, EMBASE were searched for relevant articles. The meta-analysis was finally based on 11 studies that included 1,439 patients, and combined HR was 1.66 (95% confidence intervals (CI: 1.37-2.01). Its effect also appeared significant when the analysis was restricted to tumor cell expression and patients with adenocarcinoma (HR 2.08 (95% CI: 1.24-3.48)). This study supported the fact that MMP-2 could be included in further prospective trials studying prognostic factors in NSCLC.
Collapse
Affiliation(s)
- Qian Qian
- Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing 210002, China
| | | | | | | | | | | | | |
Collapse
|
1440
|
Gubens MA, Wakelee HA. Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. LUNG CANCER-TARGETS AND THERAPY 2010; 1:63-76. [PMID: 28210107 DOI: 10.2147/lctt.s6499] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Docetaxel, a semisynthetic taxane, was the first agent to show efficacy in the second-line treatment of non-small cell lung cancer (NSCLC), and has since become a mainstay of NSCLC therapy. We review its mode of action, pharmacology, toxicity and efficacy and describe both its established role in the treatment of NSCLC and future directions in research. Docetaxel works primarily by promoting microtubule assembly and polymerization, and through this hyperstabilization, causes cell cycle arrest and death. The primary toxicity of docetaxel is neutropenia, which can be mitigated by weekly administration in selected patients. Less common toxicities are peripheral edema, which can be reduced by appropriate premedication and interstitial pneumonitis. Hypersensitivity reactions are less frequent than with paclitaxel. Docetaxel has shown a survival and quality of life advantage as a single agent first- and second-line versus placebo, as well as first-line in a platinum-based doublet therapy compared to a single agent. Increasingly docetaxel has also been used effectively in adjuvant regimens in earlier stages of the disease. Future areas of research include combinations with novel targeted therapies, and a greater understanding of biomarkers that might help predict efficacy and personalize therapy.
Collapse
Affiliation(s)
- Matthew A Gubens
- Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
| | - Heather A Wakelee
- Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
1441
|
Dijkman BG, Schuurbiers OCJ, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JNH, Snoeren MM, Oyen WJG, van der Heijden HFM, de Geus-Oei LF. The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging 2010; 37:2037-47. [PMID: 20533031 PMCID: PMC2948164 DOI: 10.1007/s00259-010-1505-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Accepted: 05/19/2010] [Indexed: 12/22/2022]
Abstract
Purpose In lung cancer patients with multiple lesions, the differentiation between metastases and second primary tumours has significant therapeutic and prognostic implications. The aim of this retrospective study was to investigate the potential of 18F-FDG PET to discriminate metastatic disease from second primary lung tumours. Methods Of 1,396 patients evaluated by the thoracic oncology group between January 2004 and April 2009 at the Radboud University Nijmegen Medical Centre, patients with a synchronous second primary lung cancer were selected. Patients with metastatic disease involving the lungs served as the control group. Maximum standardized uptake values (SUVs) measured with 18F-FDG PET were determined for two tumours in each patient. The relative difference between the SUVs of these tumours (∆SUV) was determined and compared between the second primary group and metastatic disease group. Receiver-operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of the ∆SUV for an optimal cut-off value. Results A total of 37 patients (21 metastatic disease, 16 second primary cancer) were included for analysis. The ∆SUV was significantly higher in patients with second primary cancer than in those with metastatic disease (58 vs 28%, respectively, p < 0.001). The area under the ROC curve was 0.81 and the odds ratio for the optimal cut-off was 18.4. Conclusion SUVs from 18F-FDG PET images can be helpful in differentiating metastatic disease from second primary tumours in patients with synchronous pulmonary lesions. Further studies are warranted to confirm the consistency of these results.
Collapse
Affiliation(s)
- Bernadette G. Dijkman
- Department of Pulmonary Diseases 454, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Olga C. J. Schuurbiers
- Department of Pulmonary Diseases 454, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Dennis Vriens
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Monika Looijen-Salamon
- Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Johan Bussink
- Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Johanna N. H. Timmer-Bonte
- Department of Pulmonary Diseases 454, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
- Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Miranda M. Snoeren
- Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Wim J. G. Oyen
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Henricus F. M. van der Heijden
- Department of Pulmonary Diseases 454, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Lioe-Fee de Geus-Oei
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| |
Collapse
|
1442
|
Zhao H, Gu J, Xu H, Yang B, Han Y, Li L, Liu S, Yao H. [Meta-analysis of the relationship between passive smoking population in China and lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:617-23. [PMID: 20681450 PMCID: PMC6015159 DOI: 10.3779/j.issn.1009-3419.2010.06.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Revised: 03/08/2010] [Indexed: 01/11/2023]
Abstract
BACKGROUND AND OBJECTIVE Studies of passive smoking exposure in China however are of particular interest, because of the high lung cancer rate in people who are mostly non-smokers. The aim of this study is to explore the relationship between passive smoking and lung cancer among non-smoking Chinese. METHODS By searching Medline, PubMed, CENTRAL (the Cochrane central register of controlled trials), CBM, CNKI and VIP, et al, we collected both domestic and overseas published documents between 1987 and 2007 on passive smoking and lung cancer among non-smoking Chinese. Random or fixed effect models were applied to conduct meta-analysis on the case control study results, and the combined odds ratio (OR) and the 95% confidence interval (CI) were calculated as well. RESULTS Sixteen documents were included into the combined analysis, which indicated that there was statistical significance between passive smoking and lung cancer (OR = 1.13, 95% CI: 1.05-1.21, P = 0.001). It was significant of lung cancer among non-smoking subjects associated with amount of tobacco passively smoked more than 20 cigarettes daily, with life period in adulthood passive smoking exposure, with gender female, and with exposure to workplace. The P value, OR and 95% CI were P = 0.0003, OR = 1.78, 95% CI: 1.30-2.43; P = 0.0001, OR = 1.50, 95% CI: 1.23-1.83; P = 0.000 7, OR = 1.50, 95% CI: 1.19-1.90; P < 0.0001, OR = 1.41, 95% CI: 1.19-1.66; respectively. And there was no significant difference between passive smoking and lung cancer with amount of tobacco passively smoked within 20 cigarettes daily, with life period in childhood passive smoking exposure, with gender male and with exposure to spouse and parents. CONCLUSION Passive smoking is an important risk factor of lung cancer among non-smoking Chinese, and for non-smoking women who expose to environment tobacco smoke in a long period of time have a close relationship with lung cancer risk.
Collapse
Affiliation(s)
- Hui Zhao
- Department of Thoracic Surgery, Tianjin People's Hospital, Tianjin 300121, China.
| | | | | | | | | | | | | | | |
Collapse
|
1443
|
Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 2010; 107:10737-42. [PMID: 20498076 DOI: 10.1073/pnas.1004604107] [Citation(s) in RCA: 136] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Development of cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatment side effects represent main obstacles to efficient chemotherapy of lung cancer. To overcome these difficulties, we propose inhalation local delivery of anticancer drugs in combination with suppressors of pump and nonpump cellular resistance. To test this approach, nanoscale-based delivery systems containing doxorubicin as a cell death inducer, antisense oligonucleotides targeted to MRP1 mRNA as a suppressor of pump resistance and to BCL2 mRNA as a suppressor of nonpump resistance, were developed and examined on an orthotopic murine model of human lung carcinoma. The experimental results show high antitumor activity and low adverse side effects of proposed complex inhalatory treatment that cannot be achieved by individual components applied separately. The present work potentially contributes to the treatment of lung cancer by describing a unique combinatorial local inhalation delivery of drugs and suppressors of pump and nonpump cellular resistance.
Collapse
|
1444
|
Lathan CS, Okechukwu C, Drake BF, Bennett GG. Racial differences in the perception of lung cancer: the 2005 Health Information National Trends Survey. Cancer 2010; 116:1981-6. [PMID: 20186766 DOI: 10.1002/cncr.24923] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Racial disparities in lung cancer have been described well in the literature; however, little is known about perceptions of lung cancer in the general population and whether these perceptions differ by race. METHODS Data were obtained from the 2005 Health Information National Trends Survey (HINTS) survey. The authors used a sample design of random digit dialing of listed telephone exchanges in the United States. Complete interviews were conducted with 5491 adults, including 1872 respondents who were assigned to receive questions pertaining to lung cancer. All analyses were conducted on this subset of respondents. A statistical software program was used to calculate chi-square tests and to perform logistic regression analyses that would model racial differences in perceptions of lung cancer. All estimates were weighted to be nationally representative of the US population; a jack-knife weighting method was used for parameter estimation. RESULTS Black patients and white patients shared many of the same beliefs about lung cancer mortality, and etiology. African Americans were more likely than whites 1) to agree that it is hard to follow recommendations about preventing lung cancer (odds ratio [OR], 2.05; 95% confidence interval [CI], 1.19-3.53), 2) to avoid an evaluation for lung cancer for fear that they have the disease (OR, 3.32; 95% CI, 1.84-5.98), and 3) to believe that patients with lung cancer would have pain or other symptoms before diagnosis (OR, 2.20; 95% CI, 1.27-3.79). CONCLUSIONS African Americans were more likely to hold beliefs about lung cancer that could interfere with prevention and treatment.
Collapse
Affiliation(s)
- Christopher S Lathan
- Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
| | | | | | | |
Collapse
|
1445
|
Id1 promotes tumor cell migration in nonsmall cell lung cancers. JOURNAL OF ONCOLOGY 2010; 2010:856105. [PMID: 20414347 PMCID: PMC2855985 DOI: 10.1155/2010/856105] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/12/2009] [Revised: 01/03/2010] [Accepted: 02/08/2010] [Indexed: 11/20/2022]
Abstract
Id1, which belongs to the Id family of helix-loop-helix transcription factors has been most associated with tumor progression and metastatsis; however, its significance in lung cancers has not been extensively explored. Here we seek to evaluate the expression of Id1 in a pilot study of nonsmall-cell lung cancers (NSCLCs) and determine its diagnostic and functional significance in these tumors. Paired normal and malignant lung tissues as well as a panel of NSCLC primary tumors and cell lines were evaluated for Id1 expression using Western blotting and quantitative RT-PCR. Functional assays were performed to evaluate the role of Id1 in tumor cell growth, migration and progression. We find Id1 expression is upregulated in squamous cell carcinoma when compared to adenocarcinoma of the lung and that expression of Id1 versus the normal control is variable in NSCLCs. We also note that Id1 expression in NSCLC cells is largely growth factor dependant and constitutive expression of Id1 in NSCLC cells significantly increases tumor cell migration without affecting cell proliferation. We conclude that Id1, as a mediator of tumor cell migration, may be an indicator of aggressive potential in nonsmall-cell lung cancers.
Collapse
|
1446
|
Abstract
Lung cancer is rare disease in patients under 25 years of age. It typically occurs in older patients with a history of tobacco use. This case concerns a 20-year-old man with no history of tobacco use who complained of several months of cough and lower back pain and an 11.3-kg weight loss. He was treated for pneumonia after a chest radiograph showed total opacification of the right lung. Computed tomography imaging subsequently revealed a superior right hilar mass and mediastinal lymphadenopathy. Further imaging studies showed diffuse metastatic disease. Mediastinal biopsy showed poorly differentiated epithelioid tumour with desmoplastic stromal reaction, neutrophil infiltration, and squamous differentiation. Tissue immunostaining confirmed a non-small-cell lung cancer. Unfortunately, despite aggressive therapy, the patient’s disease progressed, and he died within 9 months. In this paper, we hope to illustrate the unique challenges in diagnosing and treating young patients with metastatic lung cancer.
Collapse
Affiliation(s)
| | | | - N.J. Karlin
- Correspondence to: Nina J. Karlin, Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E. Shea Boulevard, Scottsdale, Arizona 85259 U.S.A. E-mail:
| |
Collapse
|
1447
|
Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2010; 62:970-7. [PMID: 19861557 PMCID: PMC2771853 DOI: 10.1136/jcp.2009.066548] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
There is a need for predictive biomarkers that identify non-small-cell lung cancer (NSCLC) patients most likely to respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There are numerous potential candidates, although none has been proven in prospective clinical trials. The EGFR gene copy number evaluated by fluorescence in situ hybridisation (FISH) has been highlighted as one of the most effective markers for sensitivity to EGFR TKIs in large phase III, randomised placebo-controlled trials and has been used in clinical settings to assist physicians in defining the therapeutic regimen. The EGFR FISH assay has technical challenges and it is critical that detailed guidelines are provided to help clinical laboratories in performing and interpreting the test. Excellent assay reproducibility and portability rates among laboratories are crucial to guarantee that accurate clinical decisions can be made for patients with NSCLC. This article discusses the consensus outcomes of a global workshop convened to discuss key technical issues and standardise reading strategies for the EGFR FISH assay of NSCLC tumour tissue.
Collapse
Affiliation(s)
- M Varella-Garcia
- University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1448
|
Harichand-Herdt S, Ramalingam SS. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin Oncol 2010; 36:572-80. [PMID: 19995649 DOI: 10.1053/j.seminoncol.2009.10.007] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Lung cancer is the leading cause of cancer deaths in the United States. In recent years the incidence of lung cancer in men has been declining, while in women it has been increasing. A number of population-based studies have demonstrated gender-based differences in clinical and pathologic factors, as well as in survival related to lung cancer. Disparities in age, smoking practices, and histological subtypes are among the differences that have been identified. Gender disparity also has been observed in outcomes, with improved survival observed for women in a number of clinical trials. This article reviews the gender-related differences in clinical and pathologic factors and outcomes of patients with lung cancer observed in population-based studies and clinical trials.
Collapse
Affiliation(s)
- Seema Harichand-Herdt
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
| | | |
Collapse
|
1449
|
Wang CK, Cao JG, Peng B, Gu YX, Zheng GP, He ZM. Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide. Cancer Lett 2010; 292:261-8. [PMID: 20053497 DOI: 10.1016/j.canlet.2009.12.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Revised: 12/10/2009] [Accepted: 12/11/2009] [Indexed: 01/22/2023]
Abstract
We have previously constructed a recombined vascular basement membrane derived multifunctional peptide (rVBMDMP) which can inhibit tumor growth. The aim of this study is to explore the effects and mechanisms of rVBMDMP on growth and motility/invasion in human A549 lung carcinoma cells. The effect of rVBMDMP on A549 cell viability was determined by MTT assay while the motility/invasion was measured by scratch and transwell assays. Molecules that responded to rVBMDMP treatment of A549 cells were explored using the high-throughput Cancer Pathway Finder cDNA Microarray. We identified 16 genes that were up-regulated, including GZMA, ITG alphaV, MCAM and Kiss1 and 21 genes that were down-regulated, including uPA, uPAR, CDC25A, IGF1 and FGF2. Selective differentially expressed genes were further analyzed by real-time quantitative PCR and Western blot analysis. These findings contribute to the understanding of the molecular mechanisms mediating rVBMDMP action, and suggest that rVBMDMP is a promising novel agent for the treatment of human lung carcinoma.
Collapse
Affiliation(s)
- Cheng-kun Wang
- Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha 410078, Hunan, China
| | | | | | | | | | | |
Collapse
|
1450
|
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2009; 29:1588-97. [PMID: 19966866 PMCID: PMC2841700 DOI: 10.1038/onc.2009.452] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Germline TSC1 or TSC2 mutations cause Tuberous Sclerosis Complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice were generated in which Tsc1 loss and KrasG12D expression occur in a small fraction of lung epithelial cells. Mice with combined Tsc1-KrasG12D mutation had dramatically reduced tumor latency (median survival 11.6 – 15.6 weeks) in comparison to KrasG12D alone mutant mice (median survival 27.5 weeks). Tsc1-Kras G12D tumors showed consistent activation of mTORC1, and responded to treatment with rapamycin leading to significantly improved survival, while rapamycin had minor effects on cancers in KrasG12D alone mice. Loss of heterozygosity for TSC1 or TSC2 was found in 22% of 86 human lung cancer specimens. However, none of 80 lung cancer lines studied showed evidence of lack of expression of either TSC1 or TSC2 or a signaling pattern corresponding to complete loss. These data indicate Tsc1 loss synergizes with Kras mutation to enhance lung tumorigenesis in the mouse, but that this is a rare event in human lung cancer. Rapamycin may have unique benefit for lung cancer patients in which TSC1/TSC2 function is limited.
Collapse
|